NX-1607 (Cbl-b-IN-3): Mechanism of Action

NX-1607 (Cbl-b-IN-3) MOA:Targeting CBL-B/MAPK/ERK Pathway for Solid Tumor Immunotherapy

🎯 check NX-1607 (Cbl-b-IN-3) product page

NX-1607 is a potent and selective Casitas B-lineage lymphoma-b (Cbl-b) E3 ubiquitin ligase inhibitor. It affects T cell receptor (TCR) signaling by blocking Cbl-b-mediated ubiquitination of target proteins, effectively promoting T cell activation and enhancing anti-tumor immunity.

Primary Applications and Mechanism of Action